Plasma infrared molecular fingerprinting for prostate cancer detection: Prospective evidence for a partially PSA-independent signal.

Plasma infrared molecular fingerprinting detected prostate cancer-associated variation in a pre-treatment diagnostic setting, including information partly independent of prostate-specific antigen.

However, discrimination was modest in the clinically relevant prostate cancer-versus-BPH comparison and did not exceed prostate-specific antigen in the overall cohort.

These findings support further evaluation of infrared molecular fingerprinting as an adjunctive molecular-profiling approach, requiring independent multicentre validation, clinically significant prostate cancer endpoints, and demonstration of additive value within established diagnostic pathways.